Data / Drug companies / Teva Pharmaceuticals USA, Inc.
Teva Pharmaceuticals USA, Inc.: 29 products in the FDA NDC directory, labeler code 51759
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Teva Pharmaceuticals USA, Inc. (labeler code 51759) lists 29 products in the FDA National Drug Code Directory, covering 6 finished drugs by generic name. By type: 29 prescription drugs. Its main marketing category is biologics (BLA). The newest product started marketing on November 2, 2026.
The request: Watch Teva Pharmaceuticals USA, Inc. (FDA labeler code 51759): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 51759
- Products in commercial distribution
- 29
- Packages
- 40
- Finished drugs by generic name
- 6
- Prescription products
- 29
- Over the counter products
- 0
- Flagged as original packager
- 14 of 14 products that carry the flag
- Started marketing in the last 12 months
- 7
- Earliest marketing start
- September 15, 2018
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Biologics (BLA) | 19 | 65.5% |
| New drug applications (NDA) | 10 | 34.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 29 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Adalimumab-ryvk | 9 | 3 |
| Risperidone | 7 | 43 |
| Ustekinumab-aekn | 7 | 2 |
| Olanzapine | 3 | 49 |
| Fremanezumab-vfrm | 2 | 1 |
| Eculizumab-aagh | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Kit | 12 | 41.4% |
| Injection, solution | 8 | 27.6% |
| Injection, suspension, extended release | 7 | 24.1% |
| Injection | 2 | 6.9% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Atypical Antipsychotic | 7 |
| Interleukin-12 Antagonist | 7 |
| Interleukin-23 Antagonist | 7 |
| Complement Inhibitor | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Weltruza | 51759-349 | Kit | New drug applications (NDA) | November 2, 2026 |
| Weltruza | 51759-348 | Kit | New drug applications (NDA) | November 2, 2026 |
| Weltruza | 51759-347 | Kit | New drug applications (NDA) | November 2, 2026 |
| Adalimumab-ryvk | 51759-311 | Kit | Biologics (BLA) | May 1, 2026 |
| Adalimumab-ryvk | 51759-310 | Kit | Biologics (BLA) | May 1, 2026 |
| Ustekinumab-aekn | 51759-414 | Injection, solution | Biologics (BLA) | December 23, 2025 |
| Ustekinumab-aekn | 51759-413 | Injection, solution | Biologics (BLA) | December 23, 2025 |
| Adalimumab-ryvk | 51759-361 | Kit | Biologics (BLA) | July 1, 2025 |
| Adalimumab-ryvk | 51759-360 | Kit | Biologics (BLA) | July 1, 2025 |
| Ustekinumab-aekn | 51759-710 | Injection, solution | Biologics (BLA) | June 2, 2025 |
| Ustekinumab-aekn | 51759-709 | Injection, solution | Biologics (BLA) | June 2, 2025 |
| Epysqli | 51759-208 | Injection, solution | Biologics (BLA) | April 7, 2025 |
| Selarsdi | 51759-708 | Injection, solution | Biologics (BLA) | March 12, 2025 |
| Selarsdi | 51759-607 | Injection, solution | Biologics (BLA) | March 12, 2025 |
| Selarsdi | 51759-505 | Injection, solution | Biologics (BLA) | March 12, 2025 |
| Simlandi | 51759-274 | Kit | Biologics (BLA) | February 14, 2025 |
| Simlandi | 51759-523 | Kit | Biologics (BLA) | January 29, 2025 |
| Simlandi | 51759-386 | Kit | Biologics (BLA) | January 29, 2025 |
| Simlandi | 51759-412 | Kit | Biologics (BLA) | November 19, 2024 |
| Simlandi | 51759-402 | Kit | Biologics (BLA) | May 20, 2024 |
| Uzedy | 51759-960 | Injection, suspension, extended release | New drug applications (NDA) | May 1, 2023 |
| Uzedy | 51759-850 | Injection, suspension, extended release | New drug applications (NDA) | May 1, 2023 |
| Uzedy | 51759-740 | Injection, suspension, extended release | New drug applications (NDA) | May 1, 2023 |
| Uzedy | 51759-630 | Injection, suspension, extended release | New drug applications (NDA) | May 1, 2023 |
| Uzedy | 51759-520 | Injection, suspension, extended release | New drug applications (NDA) | May 1, 2023 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.